Literature DB >> 19295476

Liver X receptor agonist GW3965 dose-dependently regulates lps-mediated liver injury and modulates posttranscriptional TNF-alpha production and p38 mitogen-activated protein kinase activation in liver macrophages.

Yun Yong Wang1, Maria K Dahle, Knut R Steffensen, Finn P Reinholt, Jon L Collins, Christoph Thiemermann, Ansgar O Aasen, Jan-Ake Gustafsson, Jacob E Wang.   

Abstract

Modulation of the host inflammatory response to infection may be a key approach to improve the outcome of patients with sepsis and organ injury. We previously reported that pretreatment of rats with the liver X receptor (LXR) agonist GW3965 reduced the liver injury associated with endotoxemia and attenuated the production of TNF-alpha by rat Kupffer cells. Here, we examine the dose-dependent effect of GW3965 on liver injury and cytokine production in a rat model of endotoxemia and explore the mechanisms underlying TNF-alpha attenuation in Kupffer cells. Low doses of GW3965 (0.1 or 0.3 mg/kg) administered 30 min before infusion of LPS and peptidoglycan significantly attenuated the increase in plasma levels of the liver injury markers alanine aminotransferase and bilirubin (6 h) as well as the inflammatory mediators TNF-alpha (1 h) and prostaglandin E2 (6 h) associated with endotoxemia. In contrast, pretreatment with a higher dose of GW3965 (1.0 mg/kg) had no such effect. Studies in primary cultures of rat Kupffer cells demonstrated that LXR agonist treatment attenuated both the secreted and cell-associated levels of TNF-alpha, whereas TNF-alpha mRNA levels were not altered. Phosphorylated p38 mitogen-activated protein kinase, which plays a major role in production of TNF-alpha at the posttranscriptional level, was attenuated by GW3965 treatment in Kupffer cells. Experiments in murine LXR-deficient Kupffer cells demonstrated enhanced production of TNF-alpha in Kupffer cells from LXR-alpha(-/-) mice when challenged with LPS compared with LXR-beta(-/-) and wild-type Kupffer cells. Taken together, these results argue in favor of a novel mechanism for LXR-mediated attenuation of liver injury by interfering with posttranscriptional regulation of TNF-alpha in Kupffer cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19295476     DOI: 10.1097/SHK.0b013e3181a47f85

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  11 in total

1.  The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver X receptors.

Authors:  Erik R Nelson; Carolyn D DuSell; Xiaojuan Wang; Matthew K Howe; Glenda Evans; Ryan D Michalek; Michihisa Umetani; Jeffrey C Rathmell; Sundeep Khosla; Diane Gesty-Palmer; Donald P McDonnell
Journal:  Endocrinology       Date:  2011-09-20       Impact factor: 4.736

Review 2.  Cytokine signaling modulates blood-brain barrier function.

Authors:  Weihong Pan; Kirsten P Stone; Hung Hsuchou; Vamshi K Manda; Yan Zhang; Abba J Kastin
Journal:  Curr Pharm Des       Date:  2011-11       Impact factor: 3.116

Review 3.  A Brief Discussion on Lipid Activated Nuclear Receptors and their Potential Role in Regulating Microglia in Age-Related Macular Degeneration (AMD).

Authors:  Mayur Choudhary; Goldis Malek
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

Review 4.  LXR agonists: new potential therapeutic drug for neurodegenerative diseases.

Authors:  Pei Xu; Dabing Li; Xiaotong Tang; Xiaohang Bao; Jing Huang; Yongping Tang; Yang Yang; Haiwei Xu; Xiaotang Fan
Journal:  Mol Neurobiol       Date:  2013-04-27       Impact factor: 5.590

5.  Function-specific intracellular signaling pathways downstream of heparin-binding EGF-like growth factor utilized by human trophoblasts.

Authors:  Philip Jessmon; Brian A Kilburn; Roberto Romero; Richard E Leach; D Randall Armant
Journal:  Biol Reprod       Date:  2010-02-03       Impact factor: 4.285

6.  The oxysterol receptor LXRβ protects against DSS- and TNBS-induced colitis in mice.

Authors:  T Jakobsson; L-L Vedin; T Hassan; N Venteclef; D Greco; M D'Amato; E Treuter; J-Å Gustafsson; K R Steffensen
Journal:  Mucosal Immunol       Date:  2014-05-07       Impact factor: 7.313

Review 7.  Rethinking Nuclear Receptors as Potential Therapeutic Targets for Retinal Diseases.

Authors:  Mayur Choudhary; Goldis Malek
Journal:  J Biomol Screen       Date:  2016-07-28

8.  Activation of liver X receptor reduces global ischemic brain injury by reduction of nuclear factor-kappaB.

Authors:  O Cheng; R P Ostrowski; W Liu; J H Zhang
Journal:  Neuroscience       Date:  2010-01-20       Impact factor: 3.590

9.  Treatment with TO901317, a synthetic liver X receptor agonist, reduces brain damage and attenuates neuroinflammation in experimental intracerebral hemorrhage.

Authors:  Chun-Hu Wu; Chien-Cheng Chen; Chai-You Lai; Tai-Ho Hung; Chao-Chang Lin; Min Chao; Szu-Fu Chen
Journal:  J Neuroinflammation       Date:  2016-03-11       Impact factor: 8.322

Review 10.  Liver X Receptors Regulate Cholesterol Metabolism and Immunity in Hepatic Nonparenchymal Cells.

Authors:  Kaori Endo-Umeda; Makoto Makishima
Journal:  Int J Mol Sci       Date:  2019-10-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.